AUPH · Aurinia Pharmaceuticals Inc.
$15.47
+0.29 (+1.91%)
At close · Aug 14
Market Cap
$2.06B
Shares
133.05M
Aurinia Pharmaceuticals Inc. Earnings Call Transcripts
Every quarterly earnings call for Aurinia Pharmaceuticals Inc. (AUPH) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲2266%
$21.62M
−$37.63M
'22 Q1
22-05-10
▲325.8%
$28.19M
−$35.52M
'22 Q2
22-08-04
▲280.3%
$55.78M
−$8.99M
'22 Q3
22-11-03
▲21.5%
$28.43M
−$26.05M
'22 Q4
23-02-28
▲59.1%
$34.41M
−$26.21M
'23 Q1
23-05-04
▲47.2%
$41.49M
−$11.49M
'23 Q2
23-08-03
▼2.3%
$54.52M
−$13.45M
'23 Q3
23-11-02
▲58.6%
$45.09M
−$26.88M
'23 Q4
24-02-15
▲46.2%
$50.30M
−$10.75M
'24 Q1
24-03-31
▲37.8%
$57.19M
$722,000
'24 Q2
24-08-01
▲24.3%
$67.77M
$14.35M
'24 Q3
24-11-07
▲32.8%
$59.87M
$1.43M
'24 Q4
25-02-27
▲24.2%
$62.47M
$23.34M
'25 Q1
25-06-30
▲22.4%
$70.01M
$21.51M
'25 Q2
25-07-31
▲8.4%
$73.47M
$31.55M
'25 Q3
25-11-04
LATEST
▲28.8%
$77.11M
$210.79M
'25 Q4
26-02-26
Earnings call
FY25 · Q4
2026-02-26
Aurinia Pharmaceuticals Inc. Q4 FY2025 Earnings Call
Confident tone
Diagnostic and treatment paradigm strategy
Combination therapy research
Aritintercept pipeline development
Revenue
$77.11M
▲ 28.8% YoY Diluted EPS
$1.53
▲ 15200% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-04
Aurinia Pharmaceuticals Inc. Q3 FY2025 Earnings Call
Confident tone
Aritinercept development
LUPKYNIS commercial growth
Raised 2025 financial guidance
Revenue
$73.47M
▲ 8.4% YoY Diluted EPS
$0.23
▲ 130% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-07-31
Aurinia Pharmaceuticals Inc. Q2 FY2025 Earnings Call
Confident tone
Revenue and earnings momentum
LUPKYNIS commercial growth
Aritinercept (AUR200) pipeline
Revenue
$70.01M
▲ 22.4% YoY Diluted EPS
$0.16
▲ 1500% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-06-30
Aurinia Pharmaceuticals Inc. Q1 FY2025 Earnings Call
Confident tone
LUPKYNIS commercial growth
AUR200 pipeline (Phase 1 SAD)
ACR/EULAR/KDIGO guidelines and first-line positioning
Revenue
$62.47M
▲ 24.2% YoY Diluted EPS
$0.16
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-27
Aurinia Pharmaceuticals Inc. Q4 FY2024 Earnings Call
Confident tone
AUR200 pipeline development
2025 financial guidance
LUPKYNIS revenue growth
Revenue
$59.87M
▲ 32.8% YoY Diluted EPS
$0.01
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-07
Aurinia Pharmaceuticals Inc. Q3 FY2024 Earnings Call
Positive tone
LUPKYNIS commercial performance
Japan regulatory approval and Otsuka partnership
ENLIGHT-LN registry and real-world evidence
Revenue
$67.77M
▲ 24.3% YoY Diluted EPS
$0.10
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-01
Aurinia Pharmaceuticals Inc. Q2 FY2024 Earnings Call
Confident tone
Revenue and commercial growth
AUR200 pipeline development
Otsuka partnership and international expansion
Revenue
$57.19M
▲ 37.8% YoY Diluted EPS
$0.01
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-03-31
Aurinia Pharmaceuticals Inc. Q1 FY2024 Earnings Call
Confident tone
Pipeline development (AUR200 and AUR300)
Lupus nephritis market opportunity and awareness
LUPKYNIS commercial performance
Revenue
$50.30M
▲ 46.2% YoY Diluted EPS
$-0.07
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-15
Aurinia Pharmaceuticals Inc. Q4 FY2023 Earnings Call
Positive tone
Patient growth metrics
LUPKYNIS commercial performance
Physician and patient education
Revenue
$45.09M
▲ 58.6% YoY Diluted EPS
$-0.19
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-02
Aurinia Pharmaceuticals Inc. Q3 FY2023 Earnings Call
Revenue
$54.52M
▼ 2.3% YoY Diluted EPS
$-0.09
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-03
Aurinia Pharmaceuticals Inc. Q2 FY2023 Earnings Call
Revenue
$41.49M
▲ 47.2% YoY Diluted EPS
$-0.08
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-04
Aurinia Pharmaceuticals Inc. Q1 FY2023 Earnings Call
Revenue
$34.41M
▲ 59.1% YoY Diluted EPS
$-0.18
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-28
Aurinia Pharmaceuticals Inc. Q4 FY2022 Earnings Call
Revenue
$28.43M
▲ 21.5% YoY Diluted EPS
$-0.18
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-03
Aurinia Pharmaceuticals Inc. Q3 FY2022 Earnings Call
Revenue
$55.78M
▲ 280.3% YoY Diluted EPS
$-0.06
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
Aurinia Pharmaceuticals Inc. Q2 FY2022 Earnings Call
Revenue
$28.19M
▲ 325.8% YoY Diluted EPS
$-0.25
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-10
Aurinia Pharmaceuticals Inc. Q1 FY2022 Earnings Call
Revenue
$21.62M
▲ 2266% YoY Diluted EPS
$-0.27
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-28
Aurinia Pharmaceuticals Inc. Q4 FY2021 Earnings Call
Revenue
$23.40M
▼ 53.2% YoY Diluted EPS
$-0.25
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-03
Aurinia Pharmaceuticals Inc. Q3 FY2021 Earnings Call
Revenue
$14.67M
▲ 50475.9% YoY Diluted EPS
$-0.39
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-05
Aurinia Pharmaceuticals Inc. Q2 FY2021 Earnings Call
Revenue
$6.62M
▲ 22727.6% YoY Diluted EPS
$-0.37
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-06
Aurinia Pharmaceuticals Inc. Q1 FY2021 Earnings Call
Revenue
$914,000
▲ 2946.7% YoY Diluted EPS
$-0.40
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2020-12-31
Aurinia Pharmaceuticals Inc. Q4 FY2020 Earnings Call
Revenue
$50.03M
▲ 172417.2% YoY Diluted EPS
$-0.06
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-09-30
Aurinia Pharmaceuticals Inc. Q3 FY2020 Earnings Call
Revenue
$29,000
▼ 87.4% YoY Diluted EPS
$-0.34
Rev · 7q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-06-30
Aurinia Pharmaceuticals Inc. Q2 FY2020 Earnings Call
Revenue
$29,000
▲ 0% YoY Diluted EPS
$-0.24
Rev · 6q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-03-31
Aurinia Pharmaceuticals Inc. Q1 FY2020 Earnings Call
Revenue
$30,000
▲ 0% YoY Diluted EPS
$-0.23
Rev · 5q
Audio
Transcript
Slides
8-K10-Q
Showing 1–24 of 24 earnings calls
Key facts
CIK
1600620
CUSIP
05156V102
13F (30d)
264 filings
260 filers
Visit website
Investor relations